Triglycerides on the rise: should we swap seats on the seesaw?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

43 citing papers in PubMed.

1. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.European heart journal. Cardiovascular pharmacotherapy · 2024
   Trial
2. The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.Nature medicine · 2023
   Trial
3. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.Circulation · 2021 · on this map
   Trial
4. Physical exertion as a trigger of acute coronary syndrome caused by plaque erosion.Journal of thrombosis and thrombolysis · 2020
   Trial
5. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.Clinical cardiology · 2017 · on this map
   Trial
6. Residual Atherothrombotic Risk After Myocardial Infarction: Integrating Lipid, Inflammatory and Thrombotic Pathways.Journal of clinical medicine · 2026
   Review
7. Hepatic SEC16B regulates lipid homeostasis by coordinating VLDL secretion and lipid droplet expansion.The Journal of clinical investigation · 2026
   Article
8. A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids.Cardiovascular drugs and therapy · 2025
   Review
9. Intraindividual Discordance Between Remnant Cholesterol and Low-Density Lipoprotein Cholesterol Associated With Incident Stroke: Results From 2 National Cohorts.Journal of the American Heart Association · 2024
   Article
10. Fish oil supplementation modifies the associations between genetically predicted and observed concentrations of blood lipids: a cross-sectional gene-diet interaction study in UK Biobank.The American journal of clinical nutrition · 2024
    Article
11. Fish oil supplementation modifies the genetic potential for blood lipids.medRxiv : the preprint server for health sciences · 2023
    Article
12. Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT.European heart journal. Cardiovascular Imaging · 2023
    Article
13. Dietary Effects on Monocyte Phenotypes in Subjects With Hypertriglyceridemia and Metabolic Syndrome.JACC. Basic to translational science · 2023
    Article
14. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.Current atherosclerosis reports · 2023
    Review
15. The Protective Effects of Eicosapentaenoic Acid for Stress-induced Accelerated Senescence in Vascular Endothelial Cells.International journal of medical sciences · 2023
    Article
16. Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada.ClinicoEconomics and outcomes research : CEOR · 2023
    Article
17. Cardiovascular and lipid-lowering effects of a marine lipoprotein extract in a high-fat diet-induced obesity mouse model.International journal of medical sciences · 2023
    Article
18. Circadian Rhythm of Subspecies of Low-Density Lipoprotein-Cholesterol and High-Density Lipoprotein-Cholesterol in Healthy Subjects and Patients with Type 2 Diabetes.Journal of atherosclerosis and thrombosis · 2023
    Article
19. Elevated Remnant Cholesterol is Associated with Adverse Cardiovascular Outcomes in Patients with Acute Coronary Syndrome.Journal of atherosclerosis and thrombosis · 2022
    Article
20. The dawn of a new era of targeted lipid-lowering therapies.European heart journal · 2022
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as